Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6820433 | 0.84 | ACHE (0.47) | ACHEMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13338024 | 0.70 | CYP19A1 (0.44) | ACHELMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL4426149 | 0.70 | MAT2A (0.44) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL16875663 | 0.69 | ALDH1A1 (0.56) | ACHEMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3425368 | 0.68 | ALDH1A1 (0.39) | ACHEMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1116007 | 0.68 | RXRA (0.50) | ACHEMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3423087 | 0.68 | CRHBP (0.57) | LMNAALDH1A1 | |
| SCHEMBL2853654 | 0.68 | TP53 (0.49) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL6823718 | 0.67 | NTRK1 (0.40) | MEN1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL15550514 | 0.67 | ALDH1A1 (0.53) | ACHEMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-23 | — | — | US | disclosed |
| WO-2004071463-A2 | FLUOROMETHOTREXATES AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259878-A1 | Fluoromethotrexates and uses therefor | MTX1, DHFR, SLC46A1 | ACHE 4842/4885MEN1 242/4885KMT2A 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.